| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.048 | 0.8 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |